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The objective of the present study was to develop diclofenac sodium tablets from 
polymeric matrices [HPMC K-15 and Eudragit NE 30D] and characterization of its 
physicochemical properties, invitro release studies by using different disintegrants 
like sodium starch glycollate and polyplasdone in different ratios to optimize its 
release profile with the standard market product. Matrix tablets were prepared by 
wet granulation method using PVP K30 as binding agent. The method of preparation 
of matrix system and its concentration were found to have pronounced effect on 
the release of diclofenac sodium The matrix tablets were evaluated for its thickness, 
hardness, friability, weight variation, drug content and invitro release studies. The 
drug delivery was analyzed using the paddle method according to USP XXIII, all 
the studies were done in phosphate buffer pH 6.8. The dissolution release profile of 
formulation made with Eudragit NE 30 D (10%w/w) with polyplasdone (2%w/w) 
was comparable with the market formulation and the f1 and f2 value were found to 
be 6.28 and 67.17. Stability studies were carried out as per ICH guidelines and tested 
for its physicochemical properties and invitro studies. The stability study results 
revealed that the prepared formulation was stable in the stress condition. 
KEYWORDS: Diclofenac sodium. HPMC. Eudragit NE 30D. Sustained release matrix. 
Tablet disintegrant.
RESUMEN
El objetivo del presente estudio fue desarrollar comprimidos de diclofenaco sódico 
en matrices poliméricas (HPMC K-15 y Eudragit NE 30D) y la caracterización de 
sus propiedades fisicoquímicas, así como estudiar la liberación in vitro mediante 
diferentes disgregantes, como glicolato sódico de almidón y poliplasdona en varias 
concentraciones, para optimizar su perfil de liberación con el producto estándar 
del mercado. Los comprimidos de la matriz se prepararon mediante el método de 
granulación húmeda usando como aglutinante PVP K30. El método de preparación 
del sistema de la matriz y su concentración resultó tener un efecto pronunciado en 
la liberación de diclofenaco sódico. Los comprimidos se evaluaron según su espesor, 
dureza, friabilidad, variación de peso, contenido farmacológico y estudios de 
liberación in vitro. La liberación del fármaco se analizó a través del método Paddle. 
Conforme a la normativa USP XXIII, todos los estudios se realizaron en buffer fosfato 
con un pH de 6,8. El perfil de liberación de la disolución de la formulación hecha 
con Eudragit NE 30D (10%w/w) y poliplasdona (2%w/w) fue comparable a la 
formulación comercial y los valores f1 y f2 fueron de 6,28 y 67,17 respectivamente. 
Se llevaron a cabo estudios de estabilidad según las normas ICH para evaluar las 
propiedades fisicoquímicas y los estudios in vitro. Los resultados de los estudios de 
estabilidad revelaron que la formulación preparada era estable en la condición de 
estrés. 
PALABRAS CLAVE: Diclofenaco sódico. HPMC. Eudragit NE 30D. Matriz de liberación 
sostenida. Comprimido de desintegración.
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INTRODUCTION
Treatment of a disease in most cases requires maintaining a 
desired drug plasma concentration level over a prolonged 
period of time. Such clinical needs often are satisfied by 
a multiple dose therapy, which can involve frequently 
dosing of two to four doses per day. The most common 
approach to minimizing patient non-compliance is by 
using extended release drug delivery systems to decrease 
the number of doses.
NSAID’s are amongst the most commonly prescribed 
medications in the world attesting to their efficiency as anti-
inflammatory, anti-thrombotic, anti-pyretic and analgesic 
agents.1 Number of processes has been developed in 
modified release oral forms to avoid frequent dosage. Oral 
controlled release dosage forms have been developed and 
studied to restrict systems to specific regions as well as to 
improve the pharmacological activity and to reduce toxic 
effects.2 Incorporation of the drug in a matrix containing 
a hydrophilic or rate controlling polymer is a method of 
fabricating controlled release formulations.3,4 The matrix 
system is commonly used for manufacturing sustained 
release dosage forms because of its easy manufacturing 
process. Hydrophilic matrix systems are among the most 
widely used for controlling drug release from solid dosage 
forms.5 The adjustment of the polymer concentration, 
viscosity grade and the addition of different types and 
levels of excipients can modify the drug release rate.6-8 
Diclofenac sodium, a potential non-steroidal anti-
inflammatory drug with pronounced analgesic properties, 
is used in the long-term treatment of rheumatoid arthritis, 
osteoarthritis and ankylosing spondylitts. Its biological 
half-life has been reported as 1 –2 h.9-10
The objective of the present study was to develop 
diclofenac sodium tablets from polymeric matrices and 
characterization of its invitro release profile by using 
different disintegrants like sodium starch glycollate and 
polyplasdone in different ratios and to optimize its release 
profile with the standard market product. 
MATERIALS AND METHODS
Materials
Diclofenac sodium, Eudragit NE 30D, HPMC K-15M, 
lactose, talc, magnesium stearate, PVP K-30, sodium starch 
glycollate and polyplasdone were procured from Inventis 
Drug Delivery systems Pvt Ltd. Potassium dihydrogen 
phosphate, sodium chloride and sodium hydroxide were 
procured from Nice Chemicals, India.
Diclofenac sodium calibration curve
Calibration curve of Diclofenac sodium was prepared 
using buffer pH 6.8 in the concentration range from 5 to 
30µg/ml.  The drug was analyzed spectrophotometrically 
(UV 1601 Shimadzu, Japan) at 285 nm.
Formulation and preparation of matrix tablets
Eighteen batches of diclofenac sodium tablets were 
prepared by utilizing Eudragit NE 30 D and HPMC K-15 
M as polymeric matrix forming material. Formulations 
were made by wet granulation technique using PVP K30 
(5%). Diclofenac sodium was blended with lactose and 
matrix forming polymer in a planetary mixer for 5 min and 
granulated with PVP K-30 (5%) and dried in hot air oven at 
50°C for 3 hrs. Tablets were prepared from these granules 
after addition of talc, magnesium stearate and the particular 
level of the disintegrant chosen for the formulation and 
compressed in a 16-station rotary tabletting machine. The 
composition of the formulation is shown in table 1 and 2.
Drug-excipient interaction studies
Preformulation studies are very important for the successful 
formulation of any dosage form. Differential Scanning 
Calorimetry (DSC) and Fourier Transform Infrared 
spectroscopy (FTIR) were used for the evaluation of 
physicochemical compatibility and interactions, which helps 
in the prediction of interaction of the drug with polymers, 
diluents and lubricants used in the tablet formulations. The 
earlier investigations recommended that 1:1 ratio of drug 
excipients maximizes the possibility of interaction and 
helps in easier detection of incompatibilities.11,12. Therefore, 
in the present study 1:1 ratio was used for preparation of 
physical mixtures and analyzed for compatibility studies.
Differential scanning calorimetry (DSC)
Differential Scanning Calorimetry (DSC) study was carried 
out using DSC 60, having TA60 software, Shimadzu, 
Japan. The instrument is very versatile as far as interaction 
and compatibility studies at pre-formulation stage was 
concerned and used to evaluate melting point, enthalpy 
changes and glass transition temperatures of drug with 
excipients and polymers. Diclofenac Sodium was mixed 
with the excipients and the DSC analysis of each sample 
under the analogous conditions of temperature range 40–
300º C, heating rate at 10ºC/min, in nitrogen atmosphere 
(20ml/min) and alumina as reference. Differential Scanning 
Calorimetry (DSC) was performed on pure drug, excipients 
and composition of final formulation. 
Fourier transform infrared (FTIR) 
FTIR studies are very helpful in the evaluation of drug–
polymer interaction studies. If there is any incompatibility 
between the drugs and excipients, these can be predicted 
by changes in the functional peaks (characteristic wave 
numbers). Diffuse reflectance technique was used (400 to 4000 
cm-1), drug and various polymers were thoroughly mixed with 
300mg of potassium bromide, compressed and the spectrum 
was obtained by placing the thin pellet in light path.
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Evaluation of tablet formulations13,14
Evaluation of characteristics of powder blend 
and tablets 
The various characteristics of powder blend 
like angle of repose, bulk density, tapped 
density, compressibility index, flowability and 
drug content were studied. The formulated 
tablets were evaluated for hardness, friability, 
uniformity of weight and drug content. 
Drug content of formulated tablets 
Five tablets from each formulation were 
randomly chosen, pulverized and weighed 
equivalent to 100mg of diclofenac sodium was 
extracted with 100ml phosphate buffer (pH 
6.8). Aliquot from subsequent filtered solution 
was further diluted in phosphate buffer (pH 
6.8) in such a way that theoretical concentration 
was same as that of standard concentration. 
Resultant solutions were analyzed by using a 
UV spectrophotometer (in triplicate) and the 
average results were taken.
In vitro dissolution studies
The dissolution studies were performed in 
triplicate for all the batches in a USP XXIII 
dissolution rate test apparatus (type II).  The 
Table 1. Composition of diclofenac sodium matrix tablet
Material F1 F2 F3 F4 F5 F6 F7 F8 F9
Diclofenac sodium (mg) 100 100 100 100 100 100 100 100 100 
Lactose 20% 20% 20% 20% 20% 20% 20% 20% 20%
HPMC K-15M 20% 20% 20% 20% 20% 20% 20% 20% 20%
Sodium starch glycollate 5% 10% 20% --- --- --- --- --- ---
Polyplasdone --- --- --- 1% 2% 5% 7.5% 10% 20%
Talc 1.50% 1.50% 1.50% 1.50% 1.50% 1.50% 1.50% 1.50% 1.50%
Magnesium stearate 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50%
PVP K-30 (5%) 10% 10% 10% 10% 10% 10% 10% 10% 10%
Table 2. Composition of diclofenac sodium matrix tablet
Material F1 F2 F3 F4 F5 F6 F7 F8 F9
Diclofenac sodium (mg) 100 100 100 100 100 100 100 100 100 
Lactose 20% 20% 20% 20% 20% 20% 20% 20% 20%
Eudragit NE 30D 10% 10% 10% 10% 10% 10% 10% 10% 10%
Sodium starch glycollate 5% 10% 20% --- --- --- --- --- ---
Polyplasdone --- --- --- 1% 2% 5% 7.5% 10% 20%
Talc 1.50% 1.50% 1.50% 1.50% 1.50% 1.50% 1.50% 1.50% 1.50%
Magnesium stearate 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50% 0.50%
PVP K-30 (5%) 10% 10% 10% 10% 10% 10% 10% 10% 10%
Figure 1.   In vitro release profile of Diclofenac sodium from matrix 
tablets
Figure 2.   In vitro release profile of Diclofenac sodium from matrix 
tablets
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Table 3. Pre-compression parameters for diclofenac 
powder blend
Parameters Values
Angle of repose (0) Between 26.21 and 31.75
Bulk Density (g/cc) Between 0.477 and 0.573
Tapped density (g/cc) Between 0.549 and 0.653
Percentage compressibility Between 10.12 and 14.98
Flowability Good
release studies were performed at 100 rpm in 1000ml 
of phosphate buffer pH 6.8 at 37 ± 0.2ºC. Five milliliters 
aliquots were withdrawn at predefined intervals, and the 
volume of the dissolution medium was maintained by 
adding the same volume of fresh prewarmed dissolution 
medium. The absorbance of the withdrawn samples was 
measured spectrophotometrically at 285 nm. 
Stability studies
The formulation which showed best in vitro release was 
selected for stability studies. The accelerated stability 
studies were conducted according to the ICH guidelines 
for a period of 6 months. 
RESULTS AND DISCUSSION
Extended release pharmaceutical dosage forms have 
received much attention in recent years and highly 
desirable for providing a constant level of pharmaceutical 
agent to a patient. The nature of the delivery system is 
dictated by the properties and dose of the drug, desired 
release profile and physiological factors. Such dosage form 
not only increase patient compliance due to reduction in 
frequency of dosing, but they also reduce the severity and 
frequency of side effects as they maintain substantially 
constant blood levels and avoid fluctuations associated 
with the conventional immediate release formulations. 
Calibration curve of diclofenac sodium was found to be 
linear in phosphate buffer pH 6.8 at wavelength 285nm 
between the concentration range of 5 and 30µg/ml, the 
correlation coefficient was found to be 0.9988. 
Compatibility studies were carried out between the 
drug and the common excipients by DSC and, FTIR 
techniques. There was no considerable change observed in 
Table 4. Post compression parameters of the formulated tablets
Parameters Values Permissible limits
Thickness (mm) Between 3.20 and 3.25 ---
Weight variation (as per USP) Between 4.8 % and 5.20% < 7.5%
Hardness (kg/m2) Between 4 and 6 ---
Friability Between 0.55 and 0.85 0.5 – 1.0 %
Drug content Between 98.40 % and 99.65% 95.0 – 105.0 % w/w
melting endotherm by DSC and no new bands or shift in 
characteristic peaks appeared by FTIR. The results revealed 
that there was no interaction between the drug and the 
excipients used in the formulation.
Tablets were made by wet granulation technique in order 
to prevent segregation of the constituents of the powder 
mix, to improve flow properties of the mix and to improve 
the compaction characteristics of the mix.  
The dried powder mixtures were tested for powder 
properties like angle of repose, bulk density, tapped 
density, percentage compressibility and flowability. The 
results are shown in table 3. The evaluation results revealed 
that all the powder mixture had good flow properties.
The formulated tablets were evaluated for its physical 
properties like weight variation, hardness, friability and 
content uniformity. The results are shown in table 4. All 
the tablets were found to pass the uniformity of weight. 
Drug content of diclofenac sodium from all formulations 
was found in the range of 98.40 to 99.65%. The hardness 
of tablets from all formulations was between 4 and 6 kg/
cm2. All the formulations showed friability between 0.55 
and 0.85% indicating that the tablets could withstand the 
mechanical shock.
The performance of sustained release formulation has 
been reported to be greatly affected by physicochemical 
properties of polymer. Eighteen different combination 
of polymers with disintegrant was used to prepare the 
sustained release matrix tablets. Invitro release study 
results revealed that the release of drug was retarded with 
the proportional increase of the disintegrant concentration. 
The cumulative percentage release of formulation made 
with Eudragit NE 30D with polyplasdone 2%  after 12h was 
found to be 93.45% whereas the standard market product 
showed 91.25%, which was comparable with the market 
formulation. The release results are shown in figure 1 and 
2. Comparative dissolution profile between the optimized 
formulation and market formulation is shown in figure 
3. The similarity factor f2 was found to be 67.17; which 
indicate that the invitro release profile is comparable. 
Stability studies were carried out at 40°C and 25°C and 
tested for its physical properties and invitro release studies. 
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Statistical analysis of the mean cumulative drug release in 
phosphate buffer (pH 6.8) have shown that the differences 
are non significant (P  ≥ 0.05). A comparative in vitro release 
of the optimized formulation before and after stability 
studies indicated that there was no significant difference 
in the release rate of the formulation. Comparative in vitro 
release study result is shown in Figure 4. F14-A represents 
the cumulative percentage drug release of the formulation 
F14 before the stability studies and F14-B represents the 
cumulative percentage drug release of the formulation F14 
after the stability studies.
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